Risk categories and refractory CLL in the era of chemoimmunotherapy.
about
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaClinical implications of the molecular genetics of chronic lymphocytic leukemiaThe pathogenesis of chronic lymphocytic leukemiaGenomic and epigenomic heterogeneity in chronic lymphocytic leukemiaIntegrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaClinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.Anti-CD37 antibodies for chronic lymphocytic leukemia.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaLong-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomeMolecular pathogenesis of chronic lymphocytic leukemia.Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.What do we do with chronic lymphocytic leukemia with 17p deletion?Molecular genetics of high-risk chronic lymphocytic leukemia.New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.Emerging therapies for refractory chronic lymphocytic leukemia.Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study.Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over?Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
P2860
Q26783600-8361C11C-1D1D-4566-9171-25EE59392A1EQ26830955-4F21343B-BCC3-420C-83E3-63FAA776DE06Q27025715-902FB227-7627-49EF-A88B-C68CCA415613Q28087672-5133ED5E-28E6-45CE-A70E-47621B54F5E9Q28394721-737936F9-16B9-499D-998A-A0DBCE70F428Q33595764-B44B11CD-9C34-4A17-B60A-287BF499D8E3Q33598691-ABC85653-BF52-47AD-AA81-E2670A3B12E3Q33978930-09710A41-7721-4131-9F57-C0134A8EA3CAQ34231446-819D9C52-5180-458A-8BB8-4C636F06F17DQ34405641-7E87F483-6F23-4AC9-A6B1-6F801F790287Q34453174-A1BD9ECE-92D1-4D60-A6F8-8C27D97B2528Q34508322-7CE797C6-FCC6-44E5-B465-CA570BF02BD2Q34625543-591279C0-1818-4E5D-9F27-F14381E5709DQ34756505-8F7A6942-B2DC-472C-9F1A-44D87FA000A0Q34769213-0D7666CF-9E72-4389-9772-D133F586E49AQ35906329-872C73B8-F791-47AF-828C-CBBE6D82F3AAQ36290321-60C953FC-3133-4093-8C52-9B21D96006A4Q36544683-781E0BD9-C12D-4CFC-9271-8319616E4E5EQ36845282-CCACBED6-BAE0-42DC-AE1B-F97665C45D87Q37087424-F3FBE192-A510-4063-919C-1883E4CAD0FBQ37528942-8AAA1B10-21B1-44FA-9555-9D4D949F0F35Q37618663-E10970E4-CCDD-4408-9B55-0909C21827B6Q37697850-84B2B78B-C72F-4DBF-9A96-76EC317DE4EEQ38063170-5C99387B-833F-49BF-A1DE-6FC9A95B2C29Q38065304-D616E310-47AB-4315-994B-340F98DC0472Q38076190-6052A24E-2566-4CB5-B6D1-EAA90888A78AQ38207143-5D8F6FD6-C2DD-4698-B233-767AA134F75EQ38221083-0BD85730-2A54-4498-A540-B2722158E170Q38344296-D3977FAC-6FE8-4254-92E2-5F24EB77D43BQ39039017-E18E0563-03EC-42D2-921C-3A81086DC085Q39277021-E3114AAB-8947-4E9D-A86F-B6B33A510507Q39307476-7A1D3FBC-F4F2-4A73-BD49-46C8BB589ED9Q40303819-451F12B9-DCD8-4338-8272-AC0FB4BE03A0Q41682806-A9367E8F-6BED-487B-9392-CBFC7F457937Q41986069-03758DC3-0A03-4D20-A4ED-1F6DC6700973Q42593100-57D0F192-6458-414F-9C33-CAB995AE034AQ44306052-10D822AE-4A7C-4C60-B89B-8C71D431F23FQ45110231-9E446F69-CEE9-4B3C-B9DF-7EE71C78A30AQ46755084-597C0E8E-9274-45E9-AF4B-0A8B70DFF881Q47932240-DC8EB6FE-4887-4809-9FF7-568853AFB43F
P2860
Risk categories and refractory CLL in the era of chemoimmunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@en
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@nl
type
label
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@en
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@nl
prefLabel
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@en
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@nl
P2860
P50
P1433
P1476
Risk categories and refractory CLL in the era of chemoimmunotherapy.
@en
P2093
John G Gribben
P2860
P304
P356
10.1182/BLOOD-2011-11-312421
P407
P577
2012-03-06T00:00:00Z